drugset / Trial / NCT01529307
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.
Timeline
- Start
- 2012-06
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAS266 | Unknown | — | Intravenous |